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Abstract
Background
Survival represents the single most important indicator of successful HIV treatment. Routine
monitoring fails to capture most deaths. As a result, both regional assessments of the impact
of HIV services and identification of hotspots for improvement efforts are limited. We sought
to assess true mortality on treatment, characterize the extent under-reporting of mortality in
routine health information systems in Zambia, and identify drivers of mortality across sites
and over time using a multistage, regionally representative sampling approach.
Methods and findings
We enumerated all HIV infected adults on antiretroviral therapy (ART) who visited any one
of 64 facilities across 4 provinces in Zambia during the 24-month period from 1 August 2013
to 31 July 2015. We identified a probability sample of patients who were lost to follow-up
through selecting facilities probability proportional to size and then a simple random sample
of lost patients. Outcomes among patients lost to follow-up were incorporated into survival
analysis and multivariate regression through probability weights. Of 165,464 individuals
(64% female, median age 39 years (IQR 33–46), median CD4 201 cells/mm3 (IQR 111–
312), the 2-year cumulative incidence of mortality increased from 1.9% (95% CI 1.7%–
2.0%) to a corrected rate of 7.0% (95% CI 5.7%–8.4%) (all ART users) and from 2.1% (95%
CI 1.8%–2.4%) to 8.3% (95% CI 6.1%–10.7%) (new ART users). Revised provincial mortal-
ity rates ranged from 3–9 times higher than naïve rates for new ART users and were lowest
in Lusaka Province (4.6 per 100 person-years) and highest in Western Province (8.7 per
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100 person-years) after correction. Corrected mortality rates varied markedly by clinic, with
an IQR of 3.5 to 7.5 deaths per 100 person-years and a high of 13.4 deaths per 100 person-
years among new ART users, even after adjustment for clinical (e.g., pretherapy CD4) and
contextual (e.g., province and clinic size) factors. Mortality rates (all ART users) were high-
est year 1 after treatment at 4.6/100 person-years (95% CI 3.9–5.5), 2.9/100 person-years
(95% CI 2.1–3.9) in year 2, and approximately 1.6% per year through 8 years on treatment.
In multivariate analysis, patient-level factors including male sex and pretherapy CD4 levels
and WHO stage were associated with higher mortality among new ART users, while male
sex and HIV disclosure were associated with mortality among all ART users. In both cases,
being late (>14 days late for appointment) or lost (>90 days late for an appointment) was
associated with deaths. We were unable to ascertain the vital status of about one-quarter of
those lost and selected for tracing and did not adjudicate causes of death.
Conclusions
HIV treatment in Zambia is not optimally effective. The high and sustained mortality rates
and marked under-reporting of mortality at the provincial-level and unexplained heterogene-
ity between regions and sites suggest opportunities for the use of corrected mortality rates
for quality improvement. A regionally representative sampling-based approach can bring
gaps and opportunities for programs into clear epidemiological focus for local and global
decision makers.
Author summary
Why was this study done?
• Previous studies from cohorts in South Africa and parts of East Africa have suggested
that site-level reporting of mortality is incomplete.
• We wanted to understand the degree to which this phenomenon was impacting HIV
outcomes at a broader scale, in this case at the provincial level in Zambia, a country with
one of the highest burdens of HIV.
• We also wanted to gain an in-depth understanding of differences between the outcomes
of clinical care sites in order to assess the role of mortality as a potential quality improve-
ment target.
What did the researchers do and find?
• From a source population of patients in 4 provinces (Lusaka, Southern, Eastern, and
Western) who visited government-operated HIV treatment sites in these provinces, we
conducted a multistage sampling approach of a stratified selection of sites and a random
sample of patients lost to follow-up.
• Lost patients were traced and their vital status was ascertained, which was used to enable
a corrected regionally representative estimate of survival after starting antiretroviral
therapy (ART) as well as corrected site-specific mortality estimates.
Mortality on HIV treatment in Zambia
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• Of 165,464 individuals, the 2-year cumulative incidence of mortality increased from
1.9% to 7.0% for all ART users and from 2.1% to 8.3% for new ART users, and provin-
cial-level mortality rates rose 3- to 8-fold once corrected for true outcomes.
• Being late (>14 days late for appointment) or lost (>90 days late for an appointment)
was associated with death.
What do these findings mean?
• Deaths are under-reported within the Zambian HIV program, and mortality rates are
highly variable across sites and provinces.
• Our findings enable national- and global-level policy makers to correct existing under-
estimates of mortality, link these data to quality improvement efforts, and reprioritize
interventions to target regional and site-level reductions in mortality as a goal of HIV
programs.
• We have also established that this methodology is feasible for use as a representative sur-
veillance tool for accurate monitoring of provincial and potentially national levels of
mortality, even as vital status registries and data systems are further developed and
strengthened.
Introduction
As the global response to HIV moves towards universal treatment, with the intent of ending
AIDS as a public health crisis by 2030, a rigorous understanding of contemporary program
effectiveness demonstrates progress as well as identifies important opportunities for improve-
ment [1]. Although other metrics also contain important information, mortality captures pro-
gram effectiveness better than any other single process or clinical outcome. For example,
although plasma HIV RNA suppression is a critical measure of HIV control and uncontrolled
viremia indicates immunological deterioration, suppressed HIV RNA does not reflect benefits
from other aspects of care such as isoniazid preventative therapy, management of side effects,
or treatment of opportunistic infections. Of note, even 90-90-90 [2]—a centrally important set
of metrics of national program performance—does not include monitoring of a program’s suc-
cess in saving lives.
Despite the importance of mortality, relatively little data exist about long-term survival after
initiation of HIV treatment in lower- and middle-income countries [3]. In South Africa, a new
National Population Register for recording vital status has enabled an advanced understanding
of mortality, but most high-burden settings lack such registries [4,5]. Routine monitoring and
evaluation of treatment programs also fail to capture most deaths because they often happen
outside of the health system in patients considered “lost to follow up” [6,7]. A nomogram has
been proposed that incorporates the results of some of these tracing studies and uses the frac-
tion of individuals lost to assess mortality, but it is not always highly accurate at site-level esti-
mates [8]. Efforts have been undertaken to understand the “true” mortality rates through
tracing random samples of patients lost to follow-up in convenience samples of clinics in mul-
tiple studies [9–11], but this approach has only been examined in the context of a limited num-
ber of conveniently sampled facilities. Mathematical models for the Joint United Nations
Mortality on HIV treatment in Zambia
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Programme on HIV/AIDS (UNAIDS) and others report on mortality but depend on a number
of assumptions and limited underlying epidemiological data [12].
In order to rigorously assess mortality, we apply for the first time, to our knowledge, a mul-
tistage sampling design to obtain representative estimates of mortality in 4 provinces in Zam-
bia as well as site-level estimates with enough precision to identify site-to-site variation. This
approach offers a rigorous estimate of (1) the magnitude of deaths after starting antiretroviral
therapy (ART) among those already on treatment at the start of the study and among new
treatment initiates, (2) when deaths occur, (3) which groups are at highest risk of death, and
(4) whether these factors differ by region, facility, or other important factors such as prior
healthcare utilization patterns. Both the approach and findings have implications for assess-
ment of program effectiveness and program improvement efforts.
Methods
The protocol and study were approved by the University of Zambia Biomedical Research Eth-
ics Committee (UNZABREC) (004-06-14) and the IRB of the University of Alabama, Birming-
ham, School of Medicine (F160122006), and the submitted protocol is available in the
supplemental material. In this paper, we used a number of analytic innovations not specified
in the analysis protocol, including the use of a modified Lorenz curve to depict the distribution
of deaths across facilities and survival analyses of mortality in which deaths are classified by
retention histories. In addition, analyses of pretreatment experience as specified in the proto-
col are also planned but not included in this paper.
Population and sampling
The target population for this analysis is the contemporary population of HIV-infected adults
on ART in Zambia. We considered “contemporary” to be patients who had a clinical encoun-
ter while on ART (including the ART initiation visit) in the 24 months before the evaluation,
and they are referred to as “all ART users” and provide the most complete picture of treatment
outcomes. We also designate a subpopulation of this group as “new ART users,” i.e., those who
initiated ART during the 24-month period prior to the evaluation—this group is more readily
comparable to outcomes from other analyses of those starting ART. Our source population
consisted of patients in 4 provinces (Lusaka, Southern, Eastern, and Western) who visited gov-
ernment-operated HIV treatment sites in these provinces, each of which receives technical
assistance support from Centre for Infectious Disease Research in Zambia (CIDRZ), a local
Zambian organization.
The analysis population was enumerated using a multistage sampling approach to yield esti-
mates representative of the entire population of patients on treatment as well as to enable com-
parison, through stratification, across 4 provinces and 3 facility types (hospital, urban health
center, and rural health center). We selected using probabilities proportional to size a mini-
mum of 2 to 10 facilities from each of 12 strata defined by facility type and province for a total
of 32 facilities. In each selected facility, we enumerated all adults on ART who made a visit in
the previous 24 months and identified loss to follow-up from this cohort (defined as>90 days
late at the time of sampling). From patients lost to follow-up, we selected a simple random
sample for tracing inverse proportional to size. This approach seeks to enable both a regionally
representative estimate of survival after starting ART and site-specific estimates with approxi-
mately 95% confidence estimates from 5% to 15% in a setting where mortality is estimated to
be 10% [9]. We additionally used simulation to optimize the sampling strategy to achieve these
aims. A diagram detailing the sampling process and tracing outcomes is presented in the sup-
plementary materials (S1 Fig).
Mortality on HIV treatment in Zambia
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Procedures and measurements
As described in previous work, we used data from an electronic medical records system to
enumerate the cohort and to obtain sociodemographic and clinical data. Peer health workers
traced lost patients intensively in the community to ascertain vital status [13]. Tracing
included in-depth review of paper and electronic medical records, phone calls, and in-person
tracing in the community. Tracers used bicycles, public transportation, study vehicles, or
motorcycles as needed. A minimum of 3 tracing attempts was required. If patients were found
to be dead, death dates, cause of death, and location of death were solicited from family and
other close contacts. The list of patients to be traced was ranked in random order and released
in blocks of 25 to each facility to preserve the benefits of a random sample.
Analysis
We estimated the cumulative incidence of mortality using the Kaplan Meier (KM) approach as
well as simple mortality rates. In KM estimates, we treated time zero as the date of ART initia-
tion. Patients who started ART before the observation period were left-truncated, which yields
an estimate of survival after ART initiation during the 2-year period of observation of this
study that is contingent on surviving into this period. This approach is analogous to life expec-
tancy estimates. Mortality estimates were carried out for all ART users as well as stratified by
new ART initiators during the 2-year observation period and those already on ART at the start
of the current period. These analyses are intended to convey the totality of the contemporary
experience of the patient population, including both that of those on treatment for extended
periods of time and that of important subpopulations. We carried out mortality estimates
both using only deaths known to the program before tracing and after incorporating findings
from tracing lost patients to “correct” estimates through use of probability weights. These indi-
vidual weights were combined with facility-level weights for estimates in the entire patient
population.
In additional survival analyses, we used the Aalen Johansen method to estimate the cumula-
tive incidence of death events classified by their current and previous engagement history
using the reweighted data. We defined patients as having “died in care” if they had died within
30 days of their last visit; the remaining patients were classified as having “died out of care.” In
addition, patients were categorized as “previously lost” if they had had at least 1 episode of
being out of care for more than 90 days after an appointment in the past and returned to care
prior to our study sampling and “previously late” if they had at least 1 episode of being late for
an appointment by more than 30 days but less than 90 days prior to our study sampling. These
categories yielded 6 engagement states for the analysis [14,15]. We examined the sociodemo-
graphic (e.g., sex and age), clinical (e.g., CD4 level at ART initiation), and health systems fac-
tors (e.g., facility size) associated with mortality through simple stratification and multivariate
Poisson regression. Analytic weights inverse to the probability of missingness were used to
address missing predictor side variables under the missing-at-random assumption [16]. We
quantified site-to-site variability in mortality by examining the distribution of site-specific
mortality estimates. In order to summarize the unequal contribution to total mortality across
facilities, we used a modification of the Lorenz curve in which the y-axis displays the cumula-
tive proportion of excess deaths and the x-axis the cumulative population proportion after
adjustment for patient (e.g., sex and CD4 level at ART initiation) as well as facility factors (e.g.,
facility volume) [17]. Excess deaths are defined as deaths above a threshold of 1% at 2 years by
facility—the approximate death rate in cohorts from Europe of stable patients used to repre-
sent “ideal” outcomes [18]. The Lorenz analysis was restricted to new ART initiators in order
to minimize the effect of local, clinic-specific distribution of patient time of treatment.
Mortality on HIV treatment in Zambia
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We used 3 approaches to characterize deaths over time. First, we graphically displayed the
retention history with all patients who died represented by a single horizontal bar. The length
of the bar represents time since ART initiation, and colors represent time spent in care, late for
care (>30 days and<90 days late for a visit), or lost (>90 days late for last appointment). Sec-
ond, we examined mortality rates in each year after ART initiation among all patients as well
as only among those patients who had made a visit in the last 2 years (and therefore survived
into the current era) and tested for significance in the change over time. Third, we added time-
varying covariates—(1) engaged, never late or lost; (2) engaged, but with a history of being late
or lost; (3) late without a history of previous episodes of being late or lost; (4) late with a history
of being lost; and (5) being lost (defined as being >90 days since last appointment)—in multi-
variable regression to capture the association between lapses in retention states and mortality.
Based on the revised estimates, we quantified the fraction of deaths that fell into each category
of visit histories and in each of the segments of time after ART initiation. We calculated the
“population attributable fraction” of all deaths that occurred in each of these states—an esti-
mate of how much mortality could be avoided if all measured characteristics were set at the
lowest level of risk.
Results
Patient characteristics
In a network of 64 HIV delivery facilities operated by the Zambian Ministry of Health and sup-
ported by CIDRZ across 4 provinces, we identified a total of 165,464 individuals on ART and
who had made a visit in the 2 years before the project period (i.e., 1 August 2013 to 31 July
2015), which included 49,129 individuals newly initiating ART during that period and 116,335
individuals already on treatment at the opening of the observation period (Fig 1).
In the entire cohort (Table 1), 64% were female, the median age was 39 years (IQR 33–46),
56% attended urban facilities, about half were from Lusaka Provence (52%), median CD4 at
ART initiation was 201 cells/mm3 (IQR 111–312), and 58% were WHO stage 1 or 2 at ART
Fig 1. Flowchart depicting tracing outcomes among all patients on antiretroviral therapy (ART) and the subset of
new ART initiators during the 2-year study period at 64 facilities.
https://doi.org/10.1371/journal.pmed.1002489.g001
Mortality on HIV treatment in Zambia
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Table 1. Descriptive characteristics of the study cohort.
All ART users New ART users
All Lost Traced Vital status
ascertained
All Lost Traced Vital status
ascertained
N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%)
Total patients 165,464 28,111 2,892 2,163 49,129 10,217 993 734
Gender Female 105,745 (64) 16,870 (60) 1,705 (59) 1,254 (58) 30,858 (63) 6,236 (61) 596 (80) 428 (58)
Male 59,719 (36) 11,241 (40) 1,187 (41) 909 (42) 18,271 (37) 3,981 (39) 397 (40) 306 (42)
WHO stage at
enrolment
Stage 1 62,116 (38) 10,690 (38) 1,059 (37) 783 (36) 23,544 (48) 4,552 (45) 433 (44) 321 (44)
Stage 2 33,288 (20) 5,080 (18) 588 (20) 445 (21) 8,574 (17) 1,605 (16) 174 (18) 130 (18)
Stage 3 48,738 (29) 8,453 (30) 766 (26) 589 (27) 8,779 (18) 2,294 (22) 180 (18) 138 (19)
Stage 4 5,497 (3) 1,006 (4) 130 (4) 94 (4) 777 (2) 241 (2) 32 (3) 22 (3)
Unknown 15,825 (10) 2,882 (10) 349 (12) 252 (12) 7,455 (15) 1,525 (15) 174 (18) 123 (17)
Year of
enrolment
2004–2006 16,198 (10) 1,723 (6) 142 (5) 93 (4) 230 (0) 58 (1) 4 (0) 2 (0)
2007–2009 41,050 (25) 5,538 (20) 570 (20) 435 (20) 1,505 (3) 328 (3) 32 (3) 20 (3)
2010–2012 53,594 (32) 9,148 (33) 1,015 (35) 758 (35) 5,341 (11) 1,053 (10) 109 (11) 73 (10)
2013–2015 54,622 (33) 11,702 (42) 1,165 (40) 877 (41) 42,053 (86) 8,778 (86) 848 (85) 639 (87)
Province Eastern 29,701 (18) 3,523 (13) 553 (19) 464 (21) 9,234 (19) 1,163 (11) 170 (17) 136 (19)
Lusaka 86,688 (52) 17,754 (63) 1,284 (44) 884 (41) 25,644 (52) 6,672 (65) 444 (45) 305 (42)
Southern 24,864(15) 2,714 (10) 507 (18) 384 (18) 6,564 (13) 944 (9) 196 (20) 151 (21)
Western 24,211 (15) 4,120 (15) 548 (19) 431 (20) 7,687 (16) 1,438 (14) 183 (18) 142 (19)
Facility type Rural 16,547 (10) 3,163 (11) 633 (22) 536 (25) 5,442 (11) 1,198 (12) 227 (23) 189 (26)
Urban 92,216 (56) 17,667 (63) 1,476 (51) 1,047 (48) 28,053 (57) 6,674 (65) 540 (54) 386 (53)
Hospital 56,701 (34) 7,281 (26) 783 (27) 580 (27) 15,634 (32) 2,345 (23) 226 (23) 159 (22)
Disclosure of
HIV status at
treatment
initiation
No 2,580 (2) 642 (2) 63 (2) 41 (2) 1,293 (3) 355 (3) 26 (3) 18 (2)
Yes 142,021 (86) 24,027 (85) 2,472 (85) 1,844 (85) 43,329 (88) 8,846 (87) 871 (88) 639 (87)
Unknown 20,863 (13) 3,442 (12) 357 (12) 278 (13) 4,507 (9) 1,016 (10) 96 (10) 77 (10)
Highest
education level
None 9,660 (6) 1,674 (6) 226 (8) 170 (8) 3,100 (6) 626 (6) 90 (9) 63 (9)
Lower-mid
basic
48,175 (29) 7,606 (27) 813 (28) 599 (28) 14,462 (29) 2,785 (27) 263 (26) 195 (27)
Upper
basic/
secondary
62,154 (38) 11,542 (41) 1,098 (38) 833 (39) 19,894 (40) 4,365 (43) 392 (39) 295 (40)
College/
university
6,398 (4) 1,107 (4) 113 (4) 98 (5) 1,831 (4) 374 (4) 42 (4) 35 (5)
Unknown 39,077 (24) 6,182 (22) 642 (22) 463 (21) 9,842 (20) 2,067 (20) 206 (21) 146 (20)
Marital status Single 14,965 (11) 3,130 (14) 320 (13) 239 (13) 5,059 (13) 1,224 (15) 135 (17) 108 (18)
Married 86,091 (63) 14,422 (63) 1,493 (63) 1,147 (63) 25,988 (66) 5,281 (64) 514 (64) 386 (64)
Divorced 16,958 (12) 3,103 (14) 342 (14) 250 (14) 5,227 (13) 1,131 (14) 93 (12) 65 (11)
Widowed 16,125 (12) 2,211 (10) 228 (10) 174 (10) 3,397 (9) 603 (7) 64 (8) 46 (8)
Unknown 2,578 (2) 0 0 0 0 0 0 0
Age; years (median [IQR]) 39 (33–46) 36 (30–43) 37 (31–44) 37 (31–44) 35 (29–42) 33 (28–40) 34 (28–41) 34 (29–41)
Enrolment cd4 count; cells/
mmol (median [IQR])
224 (119–
357)
220 (115–
354)
220 (111–
362)
217 (112–352) 281 (145–
435)
254 (125–
409)
268 (121–
423)
256 (119–412)
Initiation CD4 count; cells/
mmol (median [IQR])
201 (111–
312)
201 (108–
318)
200 (103–
313)
199 (105–309) 262 (138–
388)
238 (116–
368)
226 (102–
364)
225 (111–370)
Time on ART; days (median
[IQR])
1,142 (390–
2,139)
535 (98–
1492)
102 (89–
111)
79 (64–91) 225 (63–
407)
49 (1–180) 46 (1–170) 59 (0–185)
(Continued )
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initiation. New ART users were similar demographically but had a higher median CD4 level at
ART initiation of 262 cells/mm3 (IQR 138–288), and 65% were WHO stage 1 or 2 at enroll-
ment. The median time on ART was 1,142 days (IQR 390–2,139) for all ART users in the
cohort and 255 days (IQR 63–407) in new ART starters. The median date of ART initiation for
all users was 14 February 2012 (IQR 03 June 2009–23 January 2014) and for new ART users
was 24 July 2014 (IQR 3 February 2014–23 December 2014).
Naïve and corrected mortality estimates
Routine program data before the tracing exercise suggested that 1% of all patients had died. A
total of 17% of all patients were lost to follow-up, and this fraction lost was highly variable
across clinic sites (IQR 10%–31%). Among the 28,111 lost patients from the entire cohort, we
made an attempt to trace 2,892 (10%). Tracing efforts led to updated vital status in 2,163/2,892
(75%) of patients, but ascertainment of vital status varied from 54% to 93% across all sites (S1
Table). Among patients lost to follow-up from the entire cohort, 17% (95% CI 15%–19%) had
died. Among patients lost from the group newly starting ART during the 2-year observation
period, 21% had died (95% CI 17%–25%). After incorporating outcomes from tracing into
underlying data known to the program, we found the 2-year cumulative incidence of mortality
among all ART users increased from a naive estimate of 1.9% (95% CI 1.7%–2.0%) to a sam-
ple-revised estimate of 7.0% (95% CI 5.7%–8.4%) (Fig 2). Among new ART users, sampling
changed the cumulative incidence of mortality at 2 years from a naïve estimate of 2.1% (95%
CI 1.8%–2.4%) to a revised estimate of 8.3% (95% CI 6.1%–10.7%) (Fig 2). Facility-level revised
mortality estimates ranged widely, with an IQR from 1.6 to 2.6 deaths per 100 person-years
among all patients and an IQR of 3.5 to 7.5 deaths per 100 person-years and a high of 13.4
deaths per 100 person-years among new ART initiators (Fig 2). Most facilities showed marked
differences between naïve and revised estimates, with 1 site showing a 23-fold difference in
mortality among all patients and another site showing a 14-fold difference for new ART users.
The deaths during the first year on treatment occur mostly in persons who have not missed
appointments. There is an increase over time in the fraction of deaths that occur in patients
who are either late for a visit or who have a history of being late or lost from care (Fig 3). The
cumulative incidence estimates and confidence intervals for this analysis are presented in the
supplementary materials (S2 Table). Furthermore, general categories of reported causes of
death were available for about half of the patients who died (S3 Table).
Table 1. (Continued)
All ART users New ART users
All Lost Traced Vital status
ascertained
All Lost Traced Vital status
ascertained
N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%)
Facility size; number of
patients per facility (median
[IQR])
7,566
(4,060–
60,498)
721 (411–
1,434)
592 (104–
1,496)
611 (119–1,508) 1,082
(722–
1,959)
258 (156–
512)
35 (30–364) 26 (22–31)
ART start date; date (median
[IQR])
14 Feb 2012
(03 Jun
2009–23 Jan
2014)
23 Jan
2013 (21
Jun 2010–
12 Feb
2014)
16 Dec
2012 (29
Jun 2010–
17 Feb
2014)
28 Nov 2012 (30
Jun 2010–24
Feb 2014)
24 Jul 2014
(3 Feb
2014–23
Dec 2014)
02 May
2014 (06
Dec 2013–
09 Sep
2014)
14 May
2014 (27
Dec 2013–
24 Sep
2014)
21 May 2014
(02 Jan 2014–
25 Sep 2014)
ART, antiretroviral therapy.
https://doi.org/10.1371/journal.pmed.1002489.t001
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Regional and facility-level mortality rates
Mortality varied markedly across geographical areas and facilities. At the provincial level,
revised estimates of mortality were higher than naïve estimates, ranging in all ART users from
3-fold higher in Eastern and Southern Province to 8-times higher in Lusaka Province and in
new ART users from 3-fold higher in Eastern Province to 9-fold higher in Lusaka Province
(Fig 4, S4 Table). The highest absolute mortality rates, prior to revision, were in Eastern Prov-
ince (all ART users) and Southern Province (new ART users), whereas the highest revised
mortality rates were in Western Province, followed by Southern, Eastern, and Lusaka Prov-
inces, for both all ART users and new ART users. Facility-level mortality estimates were highly
variable even within province and across facilities with similar median CD4 levels at ART initi-
ation (Fig 5).
Multivariable regression models using patient and facility characteristics at ART initiation
found that male sex, CD4 level (200 cells/μL) at ART initiation, and higher WHO stage were
associated with higher mortality in new ART users, whereas facility size and type (health cen-
ter) were protective. For those already on ART at the start of observation, male sex; province;
facility size, type, and setting; and disclosure of HIV status at treatment initiation were associ-
ated with mortality (Table 2).
A modified Lorenz curve to capture how “concentrated” mortality was across facilities
showed that approximately half (57%) of excess deaths occurred in 15% of the population (Fig
6). The Gini coefficient was 0.714, suggesting that 71.4% of deaths were not evenly distributed
across the population.
Fig 2. Naïve and revised mortality estimates among all antiretroviral therapy (ART) users (N = 165,464) and new
ART users (N = 49, 129) in (A) cumulative incidence of mortality among all ART users. (B) Cumulative incidence of
mortality among new ART users. (C) Mortality rate among all ART users. (D) Mortality rate among new ART users. PY,
person-year.
https://doi.org/10.1371/journal.pmed.1002489.g002
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Mortality in all ART users was highest during the first year of treatment at 4.6 per 100 per-
son-years (95% CI 4.0–5.5), fell to 2.9 per 100 person-years (95% CI 2.1–3.9) in the second
year, and then remained steady at approximately 1.6% per year for up to 8 years on treatment.
The overall mortality rate in this group was 1.7 per 100 person-years (95% CI 1.5–2.0), and a
test of difference in mortality rates by year on treatment for up to 10 years was not statistically
significant (p-value = 0.46). When examined alone, patients who started ART during the
observation time for this study (new ART users) displayed the highest mortality in the first 90
days of treatment, at 7.9 per 100 person-years (95% CI 6.3–10.0); this fell to 4.6 per 100
Fig 3. Proportion of patients who died after starting antiretroviral therapy (ART) by engagement status, with left truncation for
individuals on ART before the study observation period (N = 165,464). Lost was defined as having been more than 90 days late for a
visit, and late was defined as being 15–90 days late for a visit.
https://doi.org/10.1371/journal.pmed.1002489.g003
Fig 4. Naïve and revised mortality rates by province in (A) all antiretroviral therapy (ART) users (N = 165,464) and (B)
new ART users (N = 49,129). PY, person-year.
https://doi.org/10.1371/journal.pmed.1002489.g004
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person-years from 91–180 days and then fell to 3.3 per 100 person-years (95% CI 2.0–5.8).
Regression models with time-varying factors capturing changing retention status found that
being late and being lost were both associated with mortality, but a history of lateness or loss
among those in care did not predict mortality after adjustment for other sociodemographic
and clinical factors. These associations were more pronounced among all ART users than
among new ART users (Table 2).
Proportion of current deaths in windows of time on treatment
We estimated that 38.1% (95% CI 33.1%–43.4%) of mortality occurred among individuals in
their first year on treatment, while the remaining 61.8% (95% CI 56.6%–66. 9%) was distrib-
uted among patients who had been on treatment for longer periods of time (Table 3). For
patients newly starting treatment, 50.3% (95% CI 42.4%–58.2%) of all deaths occurred among
those who had no history of missed visits, while 14.0% (95% CI 9.2%–20.7%) occurred in indi-
viduals while they were late, and 31.7% (95% CI 24.5%–39.9%) occurred among individuals
while they were lost (S2 Fig). For those already on ART in the current period, 8.8% (95% CI
6.4%–12.1%) of deaths occurred among those who were always in care at the time of death,
13.7% (95% CI 9.7%–18.9%) occurred in those with a history of lateness (but who were in care
at the time of death), 29.1% (95% CI 23.1%–35.9%) occurred in those who were in care but
had a history of being lost, 11.7% (95% CI 8.1%–16.7%) occurred in individuals while they
were late, and another 36.7% (95% CI 30.1%–43.8%) occurred among individuals while they
were lost (S2 Fig).
Fig 5. (A) Facility-level mortality rate by median CD4 at treatment initiation and (B) facility-level mortality estimates by province
among all antiretroviral therapy (ART) users (N = 165,464); (C) facility-level mortality rate by median CD4 and (B) facility-level
mortality rate by province in new ART users (N = 49,129). PY, person-year.
https://doi.org/10.1371/journal.pmed.1002489.g005
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Table 2. Predictors of mortality among all antiretroviral therapy (ART) users and new ART users.
Predictors Patients starting ART during the 2-year
observation period (new ART users)
Patients already on ART at the start of the
2-year observation period (all ART users)
Model with time-zero
patient
characteristics
Model including time-
varying retention in
care
Model with time-
zero patient
characteristics
Model including time-
varying retention in
care
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-
value
HR (95% CI) p-value
Gender Female 1 0.027 1 0.057 1 0.012 1 0.052
Male 1.86 (1.07–
3.21)
1.70 (0.98–
2.95)
1.82 (1.14–
2.90)
1.59 (1.00–
2.55)
Age (per year) 1.01 (0.98–
1.03)
0.537 1.01 (0.99–
2.95)
0.274 1.00 (0.98–
1.03)
0.780 1.01 (0.99–
1.04)
0.356
Initiation CD4 count (cells/
μL)
200 1 <0.001 1 <0.001 1 0.279 1 0.305
<200 3.82 (2.08–
7.03)
3.64 (1.92–
6.91)
1.30 (0.81–
2.11)
1.30 (0.79–
2.13)
WHO stage 1 1 0.006 1 0.025 1 0.611 1 0.361
2 2.04 (1.04–
3.99)
1.82 (0.87–
3.78)
1.04 (0.54–
2.00)
1.10 (0.56–
2.17)
3 1.59 (0.78–
3.25)
1.56 (0.75–
3.23)
0.96 (0.54–
1.71)
0.92 (0.51–
1.66)
4 5.08 (1.97–
13.09)
4.74 (1.71–
13.14)
0.47 (0.15–
1.48)
0.42 (0.15–
1.19)
Province Lusaka 1 0.302 1 0.322 1 0.012 1 0.016
Eastern 1.85 (0.92–
3.75)
1.92 (0.91–
4.05)
1.83 (1.07–
3.13)
1.18 (1.04–
3.16)
Southern 1.03 (0.55–
1.92)
1.03 (0.53–
2.02)
1.78 (1.04–
3.05)
1.92 (1.12–
3.30)
Western 1.88 (0.74–
4.76)
1.84 (0.72–
4.70)
2.73 (1.32–
5.65)
2.57 (1.20–
5.49)
Facility size (per 1,000 patients) 0.99 (0.99–
0.99)
0.012 0.99 (0.99–
0.99)
0.020 0.99 (0.99–
0.99)
0.039 0.99 (0.99–
1)
0.087
Facility setting Urban 1 0.181 1 0.361 1 0.049 1 0.176
Periurban 1.11 (0.49–
2.48)
1.10 (0.46–
2.63)
0.64 (0.28–
1.46)
0.78 (0.33–
1.88)
Rural 0.47 (0.19–
1.16)
0.57 (0.23–
1.42)
0.44 (0.22–
0.86)
0.51 (0.25–
1.04)
Facility type Health center 1 0.046 1 0.087 1 0.025 1 0.069
Hospital 0.61(0.38–
0.99)
0.63 (0.37–
1.07)
0.61 (0.39–
0.94)
0.67 (0.43–
1.03)
Disclosure of HIV status at
enrolment
No 1 0.424 1 0.637 1 0.007 0.013
Yes 0.61 (0.19–
2.03)
0.72 (0.18–
2.83)
0.24 (0.08–
0.67)
0.25(0.08–
0.75)
History Engaged, never late,
never lost
~ ~ 1 <0.001 ~ ~ <0.001
Engaged, previously
late or lost
~ ~ 0.17 (0.04–
0.74)
~ ~ 0.92 (0.49–
1.74)
Late, never late or lost ~ ~ 2.57 (1.04–
6.36)
~ ~ 0.35 (0.79–
1.56)
Late, previously late or
lost
~ ~ 5.44 (1.17–
25.29)
~ ~ 3.65 (1.53–
8.68)
Lost ~ ~ 4.17 (1.59–
10.93)
~ ~ 7.18 (3.73–
13.78)
https://doi.org/10.1371/journal.pmed.1002489.t002
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Discussion
Despite the success of implementing HIV treatment in high-burden settings in Africa, we have
identified high rates of mortality among those on treatment in Zambia, substantial under-
reporting of deaths, and marked heterogeneity among provinces and sites. We applied for the
first time, to our knowledge, a multistage sampling approach that included a sample of both
sites and patients lost to follow-up in order to develop both provincially representative and
site-level revised mortality estimates for an HIV program. In a sample representing over
160,000 patients across 4 provinces in Zambia, we found that 7% of all patients and 8% of new
ART starters died within 2 years—from 10- to 20-fold higher than treated patients in Europe
[18]. Provincial mortality rates developed from routine program data under-estimated true
mortality rates in the provinces for new ART users by 3- to 9-fold, and revised mortality rates
revealed the highest mortality rates for the HIV program in Western Province, followed by
Southern, Eastern, and Lusaka. We identified important patient characteristics associated with
Fig 6. Modified Lorenz curve depicting excess mortality in new antiretroviral therapy (ART) users
(N = 49,129).
https://doi.org/10.1371/journal.pmed.1002489.g006
Table 3. Duration on antiretroviral therapy (ART) and contribution to overall mortality among all ART users.
Time since ART initiation Total person-years Mortality rate Proportion of total deaths
Estimate 95% CI Estimate 95% CI
Lower Upper Lower Upper
<1 year 43,015 4.6 4.0 5.5 0.4 0.3 0.4
1 to <2 years 32,572 2.9 2.1 3.9 0.2 0.1 0.2
2 to <3 years 27,049 1.6 1.1 2.3 0.1 0.1 0.1
3 to <6 years 66,261 1.6 1.3 2.1 0.2 0.2 0.3
6 to <8 years 30,439 1.6 1.1 2.2 0.1 0.1 0.1
8+ years 18,365 1.9 1.2 3.1 0.1 0.0 0.1
https://doi.org/10.1371/journal.pmed.1002489.t003
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short-term (e.g., CD4 level at initiation and male sex) and long-term mortality (e.g., male sex
and disclosure), as others have described [9,19]. At the site level, care in a hospital and care in
a nonurban setting were associated with a protective effect on mortality risk for all ART users,
and the size of the facility had a statistically significant but modest protective effect. Impor-
tantly, we also found that the facility itself (regardless of province) is a critical driver of sur-
vival: even after adjustment for patients and facility characteristics, mortality across facilities
ranged from 0 per 100 person years to 13.4 per 100 person years, even though the facilities in
theory receive similar support (e.g., human resources and infrastructure). We also found that
although mortality rates were highest in the first months of treatment, death rates among
those on treatment for longer periods of time remain steady and high. None of these epidemio-
logical observations would be possible using routinely collected death data, which differed
markedly from sample-revised estimates.
Although mortality from childbirth, road accidents, and other factors are indeed higher in
Africa, over 95% of the deaths ascertained in this cohort were due to “illness” rather than death
from these competing causes. We believe the potential drivers of deaths include unmet needs
for more advanced medical care, especially given the protective effect in our multivariable
model of being treated in a hospital versus a health center, which may indicate a better capacity
for advanced diagnostics and care in hospital-based clinics. Indeed, approximately half of
deaths occur relatively shortly after a clinic visit. In a previous analysis, we found that the
majority of patients who died after a recent visit had some opportunity for medical interven-
tion that was missed—a more detailed assessment of the clinical encounters before death in
these patients should be urgently undertaken [13]. At a time when public health approaches
are focused on deintensifying care through differentiated service delivery [20,21], it should be
recalled that in many cases, improving outcomes means identifying appropriate patients in
whom to escalate care.
The provincially representative nature of the study enabled a new and more nuanced
understanding of regional mortality among those newly starting ART and among the cross-
section of all ART users in a province. First, the ratio of the revised mortality rate versus the
naïve rate was highest in Lusaka Province—8-fold higher for all ART users and 9-fold higher
for new ART users—compared with the other 3 provinces (ratios between 3–5). One interpre-
tation of this is that populations in dense urban population centers such as Lusaka may be
more likely to have their mortality under-reported. Lusaka Province is dominated by the capi-
tal city and transport hub of Lusaka, which has an urban population of 2.4 million people. It is
conceivable that high mobility and/or fewer community linkages to health facilities result in
less passive reporting of mortality than in the less urban provinces. The highest absolute
revised mortality rates were in Western Province, which is a largely rural floodplain of the
Zambezi River with the lowest population density of the 4 provinces, an HIV prevalence equal
to that in Lusaka Province (16%), and limited economic activity other than cattle farming.
Although our overall multivariable analysis suggested an association of nonurban facility set-
ting with reduced mortality, health services in much of Western Province region are notori-
ously difficult to deliver and up-referrals for advanced care can be particularly challenging in
the rainy season because of flooding and long distances to higher-level facilities. We believe
these and potentially other factors may account for the high revised mortality rates in Western
Province, although further investigation is needed at the provincial and site level. Indeed, the
differences between the revised provincial mortality rates and between the ratios of the naïve
and corrected morality rates in the provinces serve as starting points for both quality improve-
ment work by provincial health offices and for further study. For example, future investigation
could examine the system- and human-level causes of low levels of passive mortality reporting
that we found across all 4 provinces, but particularly in Lusaka Province, and could investigate
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differential utilization of up-referral for sick patients by province and facility type and the asso-
ciation of provincial mortality rates with the quality and availability of advanced care services
in the region.
Our results, drawn from a sample of patients visiting HIV treatment clinics between 2013
and 2015, indicate that even in an era of expanded eligibility for therapy and rising CD4 cell
count thresholds, CD4 cell counts remain low at initiation and are a risk factor for mortality
[22,23]. With clinical guidelines in Zambia now recommending universal treatment, we expect
CD4 cell counts at treatment initiation will increase and mortality rates will decline overall.
However, we anticipate that inconsistent healthcare utilization will continue to be a threat that
could undermine potential gains. Although mortality amongst samples of lost patients has
declined in recent years [11], perhaps reflecting an overall increase in CD4 cell counts at treat-
ment initiation, our study also demonstrated that death rates remain unacceptably high even
after 1 or more years of therapy, a time period when many might assume patients to be stable.
An elevated risk of death, even years after initiating ART, was also seen in South African
cohorts with high ascertainment of mortality through their national vital status registry. Stan-
dardized mortality ratios (SMRs) (observed deaths divided by the number of deaths expected
if all patients were HIV negative) demonstrated that men in particular had elevated SMRs even
after 48 months of therapy and having started therapy with a CD4 cell count >200 cells/mm3;
women’s rates approached those of HIV-uninfected individuals by 48 months [4], a gender
differential that has been widely noted [19]. These observations problematize a number of
assumptions. First, it has been assumed that most patients on treatment for longer periods of
time will be stable and can be placed in deintensified, demedicalized groups that emphasize
social support and community-based treatment. Yet, high mortality rates in this group suggest
that time on treatment itself cannot be a reliable marker of stability. Furthermore, it is assumed
that intensive adherence support is critical only at initiation for most patients. Persistent
deaths after 2 years on treatment imply that a subset of patients is poorly adherent or retained
and that progression of HIV disease on treatment appears to be common. Therefore, effective
support for adherence that is attuned to mitigating threats to adherence over time remains a
crucial issue [24]. Previous work has suggested that adherence, as measured by medical posses-
sion ratio, is not optimal [25], and the high death rates on treatment may reflect disease pro-
gression. Finally, treatment does not fully protect individuals against tuberculosis; thus, rolling
out isoniazid preventative therapy is a priority [26].
The marked heterogeneity of mortality across facilities is a crucial and novel observation
made possible by our sampling scheme. The fact that mortality differs across facilities, even
when higher-level systems support (e.g., supply chain, information systems, and central labo-
ratory services) is relatively uniform, implies that the next generation of improvement efforts
should be focused at the facility level and with access to improved data for better decision-
making. In South Africa, where facilities are now linked to the national vital status registry,
this is already possible, but in most settings in the region, it is not. Another implication of the
site-to-site variability is that attention should be targeted to the high-volume, high-mortality-
rate facilities because the absolute reductions in mortality are likely to be the biggest through
improvements at these sites. Third, the presence of high-performing facilities suggests that
strategies such as exemplars by positive deviants—in which high-performing facilities are
brought in to assess and guide lower-performing facilities—should be explored [27]. Unex-
plained variability in small geographical areas supported by largely uniform systems spurred a
generation of improvement science in the United States through the Dartmouth Atlas and
other investigators and should be a crucial driver of improvement in the AIDS response as
well [28,29].
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Overall, our findings also imply that in Zambia and other similar settings, even if the regu-
lar use of site and subnational region-level mortality data for improvement were attempted,
inaccuracy in the underlying data would undermine the utility of the approach. As we have
shown, under-recording of mortality is the norm, and variability is masked under typical
approaches to monitoring and evaluation, as evidenced by the differences in the ordering of
mortality burden by province with use of naïve versus revised mortality rates. Although Demo-
graphic and Health Surveys (DHSs) and other door-to-door surveys provide representative
data that can be used to evaluate trends in mortality, they are often not linked to sites and are
not conducted with the frequency required to monitor for program performance and to mea-
sure the proximal effects of health systems interventions [30]. We propose 2 potential
approaches to this issue. The first is to renew existing calls for nationwide death and birth reg-
istries, an approach successfully taken to scale in South Africa [31] and now being piloted in
Zambia. Where this is not immediately possible, a scalable version of the representative multi-
stage sampling performed in this study would be a feasible approach to incorporate into
regional surveillance. Indeed, this approach is currently being adapted for broader use in Zam-
bia, and we will shortly be publishing a cost analysis and a toolkit to encourage its broader use
in the region. If efforts to expand this approach to improving our understanding of mortality
are successful and supported by governments and funders, we would ideally be able to equip
every site, district, and country with up-to-date access to accurate mortality data. In addition,
incorporation of corrected provincial mortality rates into projection models could further
improve their ability to inform resource needs and epidemic trends.
Limitations
The methodology is predicated on tracing a random sample of individuals lost to care. We
were unable to ascertain the vital status of about one-quarter of those lost and traced, which
could have biased our results. However, we did not find differences in the sociodemographic
or clinical characteristics among those who were traced and found compared with those we
were unable to find. We were also not able to adjudicate causes of death and therefore are
unable to distinguish clearly all-cause mortality versus HIV-related mortality. Further studies
are needed to better understand clinical causes of death among HIV-infected individuals on
ART in Zambia. Lastly, although the study included a comprehensive sample of Ministry of
Health (MOH) ART sites in the 4 provinces, faith-based and other sites were not included in
the estimates.
Conclusions
To our knowledge, this study is the first to apply a multistage sampling-based approach to gen-
erating provincially representative mortality rates for HIV programs in low- and middle-
income countries (LMICs). In addition to demonstrating that provincial mortality is substan-
tially under-reported and variable among HIV-infected individuals on ART, we found unex-
pectedly high site-to-site variability in mortality after starting HIV treatment under routine
health service delivery conditions. This heterogeneity among sites suggests that service delivery
has much room to improve and that greater attention to systematically generating and using
corrected mortality rates is a logical next step for ongoing quality improvement for national
programs and major donors. In addition, given the associations of late/missed visits with mor-
tality, greater attention to patient-centered and differentiated care approaches that are also
sensitive to the need for care intensification may have a role in not only improving retention
but addressing the markedly high death rates, despite the widespread use and availability of
ART.
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